These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 7762084)

  • 1. Targeting HIV-1 protease: a test of drug-design methodologies.
    West ML; Fairlie DP
    Trends Pharmacol Sci; 1995 Feb; 16(2):67-75. PubMed ID: 7762084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV protease inhibitors: peptidomimetic drugs and future perspectives.
    Abdel-Rahman HM; Al-karamany GS; El-Koussi NA; Youssef AF; Kiso Y
    Curr Med Chem; 2002 Nov; 9(21):1905-22. PubMed ID: 12369875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual selection pressure by drugs and HLA class I-restricted immune responses on human immunodeficiency virus type 1 protease.
    Mueller SM; Schaetz B; Eismann K; Bergmann S; Bauerle M; Schmitt-Haendle M; Walter H; Schmidt B; Korn K; Sticht H; Spriewald B; Harrer EG; Harrer T
    J Virol; 2007 Mar; 81(6):2887-98. PubMed ID: 17202219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the design of HIV proteinase inhibitors.
    Martin JA
    Antiviral Res; 1992 Apr; 17(4):265-78. PubMed ID: 1642479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immunodeficiency virus reverse transcriptase and protease sequence database.
    Rhee SY; Gonzales MJ; Kantor R; Betts BJ; Ravela J; Shafer RW
    Nucleic Acids Res; 2003 Jan; 31(1):298-303. PubMed ID: 12520007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 protease inhibitors: effects on HIV-2 replication and resistance.
    Menéndez-Arias L; Tözsér J
    Trends Pharmacol Sci; 2008 Jan; 29(1):42-9. PubMed ID: 18054799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
    Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of inhibitors of reverse transcriptase and protease as therapeutics against HIV infection.
    Mitsuya H
    J Enzyme Inhib; 1992; 6(1):1-8. PubMed ID: 1285300
    [No Abstract]   [Full Text] [Related]  

  • 9. Rational drug design and HIV: hopes and limitations.
    Goody RS
    Nat Med; 1995 Jun; 1(6):519-20. PubMed ID: 7585113
    [No Abstract]   [Full Text] [Related]  

  • 10. Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity.
    Logsdon BC; Vickrey JF; Martin P; Proteasa G; Koepke JI; Terlecky SR; Wawrzak Z; Winters MA; Merigan TC; Kovari LC
    J Virol; 2004 Mar; 78(6):3123-32. PubMed ID: 14990731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors.
    Mastrolorenzo A; Rusconi S; Scozzafava A; Barbaro G; Supuran CT
    Curr Med Chem; 2007; 14(26):2734-48. PubMed ID: 18045120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical benefits of resistance assay for HIV-specific protease inhibitors: when to check and in whom?
    Aizawa S; Gatanaga H; Ida S; Sakai A; Tanaka M; Takahashi Y; Hirabayashi Y; Oka S
    AIDS; 1999 Jul; 13(10):1278-9. PubMed ID: 10416536
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeting dynamic pockets of HIV-1 protease by structure-based computational screening for allosteric inhibitors.
    Kunze J; Todoroff N; Schneider P; Rodrigues T; Geppert T; Reisen F; Schreuder H; Saas J; Hessler G; Baringhaus KH; Schneider G
    J Chem Inf Model; 2014 Mar; 54(3):987-91. PubMed ID: 24528206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative studies on inhibitors of HIV protease: a target for drug design.
    Jayaraman S; Shah K
    In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in the Vif protein of HIV-1 associated with the development of resistance to inhibitors of viral protease.
    Adekale MA; Cane PA; McCrae MA
    J Med Virol; 2005 Feb; 75(2):195-201. PubMed ID: 15602725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors.
    Deforche K; Camacho R; Grossman Z; Silander T; Soares MA; Moreau Y; Shafer RW; Van Laethem K; Carvalho AP; Wynhoven B; Cane P; Snoeck J; Clarke J; Sirivichayakul S; Ariyoshi K; Holguin A; Rudich H; Rodrigues R; Bouzas MB; Cahn P; Brigido LF; Soriano V; Sugiura W; Phanuphak P; Morris L; Weber J; Pillay D; Tanuri A; Harrigan PR; Shapiro JM; Katzenstein DA; Kantor R; Vandamme AM
    Infect Genet Evol; 2007 Jun; 7(3):382-90. PubMed ID: 17127103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV protease inhibitors.
    Winslow DL; Otto MJ
    AIDS; 1995; 9 Suppl A():S183-92. PubMed ID: 8819585
    [No Abstract]   [Full Text] [Related]  

  • 19. New wave antiretrovirals.
    Smart T
    GMHC Treat Issues; 1996 Sep; 10(9):1-3. PubMed ID: 11363838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
    Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
    J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.